Enzo Biochem Inc Quick Ratio (ENZ) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Enzo Biochem Inc  (NYSE: ENZ)

Enzo Biochem Inc's Quick Ratio

ENZ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2025, Quick Ratio deteriorated to 2.27 above company average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 110 other companies have achieved higher Quick Ratio than Enzo Biochem Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 1062 to 1216.

Explain Quick Ratio?
How much Cash & cash equivalents ENZ´s has?
What are ENZ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENZ Quick Ratio (Apr 30 2025)
Q3		 (Jan 31 2025)
Q2		 (Oct 31 2024)
Q1		 (Jul 31 2024)
Q4		 (Apr 30 2024)
Q3
Y / Y Current Liabilities Change -25.54 % -33.01 % 14.24 % -38.79 % -14.34 %
Y / Y Cash & cash equivalent Change -35.8 % -33.11 % -31.03 % -36.42 % 2071.58 %
Quick Ratio MRQ 2.27 2.46 2.04 2.19 2.64
ENZ's Total Ranking # 1216 # 1062 # 714 # #
Seq. Current Liabilities Change -1.4 % -30.08 % -2.01 % 10.22 % -11.29 %
Seq. Cash & cash equivalent Change -8.94 % -15.58 % -8.85 % -8.37 % -5.12 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 111
Healthcare Sector # 519
Overall Market # 1216


Quick Ratio Statistics
High Average Low
4.19 1.82 0.06
(Apr 30 2019)   (Apr 30 2023)




Financial Statements
Enzo Biochem Inc's Current Liabilities $ 16 Millions Visit ENZ's Balance sheet
Enzo Biochem Inc's Cash & cash equivalent $ 37 Millions Visit ENZ's Balance sheet
Source of ENZ's Sales Visit ENZ's Sales by Geography


Cumulative Enzo Biochem Inc's Quick Ratio

ENZ's Quick Ratio for the trailling 12 Months

ENZ Quick Ratio

 (Apr 30 2025)
12 Months		 (Jan 31 2025)
12 Months		 (Oct 31 2024)
12 Months		 (Jul 31 2024)
12 Months		 (Apr 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -24.45 % -21.89 % -20.19 % -22.9 % 24.33 %
Y / Y Cash & cash equivalent TTM Growth -34.16 % -7.88 % 36.57 % 133.84 % 549.33 %
Quick Ratio TTM 2.22 2.32 2.33 2.64 2.55
Total Ranking TTM # 3795 # 3366 # 2878 # #
Seq. Current Liabilities TTM Growth -6.49 % -8.64 % 3.23 % -14.33 % -3.32 %
Seq. Cash & cash equivalent TTM Growth -10.36 % -9.17 % -8.99 % -11.15 % 25.42 %

Quick ratio ranking by company, industry and sector >> Back to ENZ Financial Strength Comparisons >> Go to Compare ENZ Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ENZ's Current Liabilities to $16.13 millions, cumulative Quick Ratio to 2.22 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 161 other companies have achieved higher Quick Ratio than Enzo Biochem Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3366 to 3795.

Explain Quick Ratio?
How much Cash & cash equivalents ENZ´s has?
What are ENZ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 162
Healthcare Sector # 979
Within the Market # 3795


trailing twelve months Quick Ratio Statistics
High Average Low
3.56 1.78 0.32
(Oct 31 2017)   (Jan 31 2014)




Companies with similar Quick Ratio in the quarter ending Apr 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioApr 30 2025 MRQ Cash & cash equivalentApr 30 2025 MRQ Current Liabilities
Precision Biosciences Inc  6.23 $ 77.223  Millions$ 12.393  Millions
Tenaya Therapeutics Inc   6.23 $ 88.158  Millions$ 14.152  Millions
Cargo Therapeutics Inc   6.18 $ 318.836  Millions$ 51.552  Millions
Exozymes Inc   5.89 $ 8.511  Millions$ 1.444  Millions
Voyager Therapeutics Inc   5.87 $ 236.019  Millions$ 40.212  Millions
Immunocore Holdings Plc  5.68 $ 837.030  Millions$ 147.446  Millions
Metagenomi Therapeutics Inc   5.66 $ 225.970  Millions$ 39.893  Millions
Monte Rosa Therapeutics Inc   5.51 $ 326.074  Millions$ 59.216  Millions
Fennec Pharmaceuticals Inc   5.42 $ 45.350  Millions$ 8.371  Millions
Pharmacyte Biotech Inc   5.33 $ 15.538  Millions$ 2.914  Millions
Inhibrx Biosciences Inc   5.20 $ 216.520  Millions$ 41.666  Millions
Taysha Gene Therapies Inc   5.17 $ 116.593  Millions$ 22.557  Millions
Repligen Corp  5.10 $ 697.229  Millions$ 136.842  Millions
Arcellx Inc   4.83 $ 543.265  Millions$ 112.461  Millions
Vor Biopharma Inc   4.82 $ 60.035  Millions$ 12.461  Millions
Agomab Therapeutics Nv  4.65 $ 96.788  Millions$ 20.820  Millions
Pluri Inc   4.61 $ 26.273  Millions$ 5.705  Millions
Candel Therapeutics Inc   4.59 $ 92.165  Millions$ 20.069  Millions
Kodiak Sciences Inc   4.50 $ 138.851  Millions$ 30.876  Millions
Evaxion A  4.35 $ 23.234  Millions$ 5.347  Millions
Prime Medicine Inc   4.09 $ 140.344  Millions$ 34.288  Millions
Jasper Therapeutics Inc   3.96 $ 48.799  Millions$ 12.334  Millions
Cabaletta Bio Inc   3.88 $ 131.830  Millions$ 33.989  Millions
Cardiol Therapeutics inc   3.79 $ 16.405  Millions$ 4.332  Millions
Dyadic International Inc   3.75 $ 7.349  Millions$ 1.962  Millions
Moderna Inc   3.73 $ 5,975.000  Millions$ 1,604.000  Millions
Lineage Cell Therapeutics Inc   3.66 $ 47.905  Millions$ 13.089  Millions
Biontech Se  3.61 $ 8,655.360  Millions$ 2,399.376  Millions
Passage Bio Inc   3.55 $ 63.357  Millions$ 17.825  Millions
Recursion Pharmaceuticals Inc   3.52 $ 500.453  Millions$ 141.981  Millions

Date modified: 2026-09-08T17:35:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.